Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT‐330): A report from the pediatric preclinical testing program
暂无分享，去创建一个
S. Keir | J. Maris | P. Houghton | R. Lock | E. Attiyeh | Malcolm A. Smith | R. Gorlick | Min H. Kang | Y. Landesman | S. Shacham | Jianrong Wu | R. Kurmasheva | C. Reynolds | E. Kolb | H. Carol | Dmitry Lyalin | Malcolm A. Smith | Edward F. Attiyeh | Raushan T. Kurmasheva | Stephen T. Keir | John M. Maris